Neoleukin Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Neoleukin Therapeutics has a total shareholder equity of $75.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $89.6M and $14.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$78.51m |
| Equity | US$75.24m |
| Total liabilities | US$14.35m |
| Total assets | US$89.59m |
Recent financial health updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Jul 18
Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation
Mar 10We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate
Nov 19Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?
Jun 03Recent updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Jul 18Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation
Mar 10We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate
Nov 19Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?
Jun 03Financial Position Analysis
Short Term Liabilities: NLTX's short term assets ($79.9M) exceed its short term liabilities ($5.2M).
Long Term Liabilities: NLTX's short term assets ($79.9M) exceed its long term liabilities ($9.1M).
Debt to Equity History and Analysis
Debt Level: NLTX is debt free.
Reducing Debt: NLTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NLTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NLTX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 5.7% each year.